Literature DB >> 1948472

The use of the polymerase chain reaction test in the diagnosis of tuberculosis.

P D du van Helden1, R Toit, A Jordaan, B Taljaard, J Pitout, T Victor.   

Abstract

Current techniques for laboratory diagnosis of tuberculosis have some serious limitations. These include the high cost and time required for the current assays. The development of a rapid, sensitive, specific and low-cost assay is therefore of considerable importance. We report here the development and laboratory testing of a polymerase chain reaction DNA-based diagnostic test for the presence of Mycobacterium tuberculosis in sputum. The assay shows a high level of sensitivity and specificity and requires considerably less capital, consumables and time inputs than existing laboratory tests. We believe this technology is ready for large-scale evaluation and use, particularly in hospital-based laboratories.

Entities:  

Mesh:

Year:  1991        PMID: 1948472

Source DB:  PubMed          Journal:  S Afr Med J


  4 in total

1.  Diagnostic accuracy of in-house PCR for pulmonary tuberculosis in smear-positive patients: meta-analysis and metaregression.

Authors:  S Greco; M Rulli; E Girardi; C Piersimoni; C Saltini
Journal:  J Clin Microbiol       Date:  2009-01-14       Impact factor: 5.948

2.  Polymerase chain reaction in the diagnosis of urinary tract tuberculosis.

Authors:  P van Vollenhoven; C F Heyns; P M de Beer; P Whitaker; P D van Helden; T Victor
Journal:  Urol Res       Date:  1996

3.  Large-scale use of polymerase chain reaction for detection of Mycobacterium tuberculosis in a routine mycobacteriology laboratory.

Authors:  J E Clarridge; R M Shawar; T M Shinnick; B B Plikaytis
Journal:  J Clin Microbiol       Date:  1993-08       Impact factor: 5.948

4.  In-house nucleic acid amplification tests for the detection of Mycobacterium tuberculosis in sputum specimens: meta-analysis and meta-regression.

Authors:  Laura L Flores; Madhukar Pai; John M Colford; Lee W Riley
Journal:  BMC Microbiol       Date:  2005-10-03       Impact factor: 3.605

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.